Astellas Reports Results of Mirabegron in P-IV PLUS Study to Reduce Overactive Bladder Symptoms in Men

 Astellas Reports Results of Mirabegron in P-IV PLUS Study to Reduce Overactive Bladder Symptoms in Men

Astellas Reports Results of Mirabegron in P-IV PLUS Study to Reduce Overactive Bladder Symptoms in Men

Shots:

  • The P-IV PLUS study involves assessing of Mirabegron(25mg,50mg) vs PBO in 715 men patients with overactive bladder (OAB) symptoms receiving tamsulosin for lower urinary tract symptoms (LUTS) due to underlying benign prostatic hyperplasia (BPH) aged ≥40 yrs.
  • The P-IV PLUS study results: @12wks. reduction in no. of micturition/day, increment in mean volume voided (MVV)/micturition, reduction in urgency episodes/day, improvements in total urgency and frequency score, TEAEs (25.9% vs 31.4%), no difference in IPSS score is observed
  • Mirabegron is a beta‐3 adrenergic agonist targeting CYP2D6 and has received FDA’s approval as monothx. or in combination with solifenacin succinate for the treatment of OAB symptoms, marketed as Myrbetriq in the US

Click here to read full press release/ article | Ref: PRNewsWire | Image: Student Show

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post